Uveal Melanoma UK National Guidelines

Nathan, Paul; Cohen, Victoria M L; Coupland, Sarah E.; Curtis, Kelly K.; Damato, Bertil; Evans, Jonathan; Fenwick, S.; Kirkpatrick, Lynn; Li, O.; Marshall, Ernie; McGuirk, K.; Ottensmeier, Christian; Pearce, Neil; Salvi, Sachin M.; Stedman, Brian; Szlosarek, Peter W.; Turnbull, Niruwan

doi:10.1016/j.ejca.2015.07.013

Cited by 100 publications

(84 citation statements)

References 24 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is scope for guidelines similar to those published in the UK and elsewhere for uveal melanoma, retinoblastoma and other malignancies [11,12]. On the basis of this study, we tentatively propose a short list of standards of care for patients with ocular melanoma, as a basis for discussion and refinement (Table 3).…”

Section: Discussionmentioning

confidence: 94%

The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation

et al. 2018

View full text Add to dashboard Cite

Background: Ocular melanomas threaten patients with early death, visual handicap, and loss of the eye. The aims of this study were to identify aspects of care that patients with ocular melanoma considered most important and to determine whether patients felt their needs had been adequately addressed. Methods: A cross-sectional study including US ocular melanoma patients and their caregivers. An online survey of US ocular melanoma patients was designed and conducted by the Ocular Melanoma Foundation. Results: The cohort included 180 patients with uveal melanoma and 4 with conjunctival melanoma. Median follow-up was 3 years. A third of patients reported that their uveal melanoma had initially been diagnosed as a nevus. Most uveal melanomas were treated with brachytherapy. Almost 50% of patients had no genetic tumor analysis. Screening methods reported most commonly were computed tomography and liver function tests. Metastatic disease developed in 11% of patients. Few patients (13.3%) reported an offer of psychological support. Most dissatisfaction was with lack of advice on financial aspects of care and lack of psychological counseling, with women tending to express more dissatisfaction with care. Many patients complained about the way ophthalmologists delivered bad news to them. Conclusions: This patients' perspective highlights directions for research, education, and other measures to improve the care of patients with ocular melanoma in the US and elsewhere.

show abstract

Section: Discussionmentioning

confidence: 94%

The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…While effective treatments are available for primary tumours, approximately half of patients will develop metastases within 15 years following diagnosis, for which currently there is no effective treatment [1, 2]. This has created a pressing need to understand the molecular pathogenesis of the disease.…”

Section: Introductionmentioning

confidence: 99%

Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish

et al. 2016

View full text Add to dashboard Cite

Mutations affecting Gαq proteins are pervasive in uveal melanoma (UM), suggesting they ‘drive’ UM pathogenesis. The ERK1/2-MAPK pathway is critical for cutaneous melanoma development and consequently an important therapeutic target. Defining the contribution of ERK1/2-MAPK signalling to UM development has been hampered by the lack of an informative animal model that spontaneously develops UM. Towards this end, we engineered transgenic zebrafish to express oncogenic GNAQQ209P in the melanocyte lineage. This resulted in hyperplasia of uveal melanocytes, but with no evidence of malignant progression, nor perturbation of skin melanocytes. Combining expression of oncogenic GNAQQ209P with p53 inactivation resulted in earlier onset and even more extensive hyperplasia of uveal melanocytes that progressed to UM. Immunohistochemistry revealed only weak immunoreactivity to phosphorylated (p)ERK1/2 in established uveal tumours—in contrast to strong immunoreactivity in oncogenic RAS-driven skin lesions—but ubiquitous positive staining for nuclear Yes-associated protein (YAP). Moreover, no changes were observed in pERK1/2 levels upon transient knockdown of GNAQ or phospholipase C-beta (PLC-β) inhibition in the majority of human UM cell lines we tested harbouring GNAQ mutations. In summary, our findings demonstrate a weak correlation between oncogenic GNAQQ209P mutation and sustained ERK1/2-MAPK activation, implying that ERK1/2 signalling is unlikely to be instrumental in the maintenance of GNAQQ209P-driven UMs.

show abstract

“…The natural history of uveal melanoma often involves the development of metastasis, an event associated with poor prognosis [4]. Therefore, it is imperative that the treating physician be familiar with the clinical features of uveal melanoma allowing for early treatment and aversion of potentially life-threatening metastasis [5].…”

Section: Introductionmentioning

confidence: 99%

Uveal Melanoma: A Review of the Literature

2018

View full text Add to dashboard Cite

Melanomas affecting different components of the uvea occur with differing frequencies and clinical presentations. Uveal melanoma is diagnosed via funduscopic exam and ancillary tests. These lesions may present with visual findings or incidental findings on physical exam. Metastasis occurs in approximately half of all patients with primary uveal melanoma. The liver is the most common site of metastasis. Enucleation was at one time considered the definitive local treatment for primary uveal melanoma, but has been largely replaced by other therapeutic procedures that aim to prevent metastasis while preserving vision. Unfortunately, metastasis of uveal melanoma almost always proves to be fatal. The current treatment of metastatic uveal melanoma is limited by the intrinsic resistance of uveal melanoma to conventional systemic therapies. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Early detection and therapy are important factors in disease survival. It is imperative that the treating physician be familiar with the clinical features of uveal melanoma and distinguish it from mimickers in order to ensure effective and timely treatment.

show abstract

Uveal Melanoma UK National Guidelines

Cited by 100 publications

References 24 publications

The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation

The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation

Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish

Uveal Melanoma: A Review of the Literature

Contact Info

Product

Resources

About